Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 4 2Phase NA 1

Status

Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other 4

Conditions

Breast Neoplasms 298Carcinoma, Non-Small-Cell Lung 226Neoplasms 155Prostatic Neoplasms 154Multiple Myeloma 116Neoplasm Metastasis 83Colorectal Neoplasms 80Leukemia, Myeloid, Acute 74Lung Neoplasms 71Parkinson Disease 4, Autosomal Dominant Lewy Body 68Melanoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Follicular 62Lymphoma, Non-Hodgkin 61Papillomavirus Infections 59Leukemia 59Pain 52Lymphoma 52Uterine Cervical Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Ovarian Neoplasms 47Carcinoma, Hepatocellular 46Keratosis, Actinic 44Carcinoma, Renal Cell 44Recurrence 43Head and Neck Neoplasms 43Stomach Neoplasms 38Lymphoma, Large B-Cell, Diffuse 34Urinary Bladder Neoplasms 33Squamous Cell Carcinoma of Head and Neck 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Has results × Constipation × Clear all
NCT01696643 2018-11-15

Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
1,407 enrolled 15 charts
Other

Opioid-Induced Constipation, Bronchiolitis Obliterans Syndrome, Constipation, Pain

NCT01901302 2018-11-15

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
61 enrolled 4 charts
Other

Opioid-Induced Constipation, Bronchiolitis Obliterans Syndrome, Constipation, Pain

NCT01901328 2018-11-15

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
49 enrolled 4 charts
Other

Opioid-Induced Constipation, Bronchiolitis Obliterans Syndrome, Constipation, Pain

NCT01901341 2018-11-15

The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
44 enrolled 6 charts
Other

Opioid-Induced Constipation, Bronchiolitis Obliterans Syndrome, Constipation, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡